AAOS: Best TKA Outcome at Very-High Volume Hospitals

Share this content:
AAOS: Best TKA Outcome at Very-High Volume Hospitals
AAOS: Best TKA Outcome at Very-High Volume Hospitals

MONDAY, March 7, 2016 (HealthDay News) -- Undergoing total knee arthroplasty (TKA) at very-high volume hospitals is associated with the lowest lifetime costs and greatest benefits, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 1 to 5 in Orlando, Fla.

Jayme C. Burket, Ph.D., from the Hospital for Special Surgery in New York City, and colleagues compared the cost-effectiveness of primary elective unilateral TKA over a patient's lifetime among low, medium, high, and very-high volume hospitals using data from the New York Statewide Planning and Research Cooperative System from 1997 to 2014 for young (89,796 cases) and Medicare-age (111,492 cases) cohorts.

The researchers found that the lowest lifetime costs and greatest benefits were seen for TKA surgery performed at very-high volume hospitals in the young cohort (costs: $45,684; $43,222; $41,244; and $29,899, for low, medium, high, and very-high volume hospitals, respectively; corresponding benefits: 17.07, 17.15, 17.19, and 17.22, quality-adjusted life-years). Similar results were seen in the Medicare cohort, although the cost savings were more modest. Total societal cost savings would be approximately $23 million annually if patients from low, medium, and high volume hospitals in New York State regionalized to very-high volume hospitals.

"We found that knee replacement surgery at higher-volume hospitals is less costly over a patient's lifetime and provides better outcomes," Burket said in a statement.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »